ClinicalTrials.gg
Active, not recruitingNCT05777967Updated Feb 2, 2024

Efficacy and Safety of FF-31501 in Meniscus Tear Patients

A Phase 3 interventional study of human autologous synovial stem cells in Meniscus Injury, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Active, not recruiting at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A single-arm, multi-center study to verify that knee joint function at 52 weeks after injection of FF-31501 is better than at screening in patients with meniscus tear who are eligible for meniscectomy .

02

Conditions studied

  • Meniscus Injury
03

In context

Lead sponsor

FUJIFILM Toyama Chemical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with suspected meniscal flap tear
  2. Patients with knee pain
  3. Patients with one or more of the following symptoms

    • Feeling stuck in the knee・Instability of the knee
    • Knee range of motion impairment
    • Knee joint edema
  4. Other

Exclusion criteria

Exclusion Criteria:

  1. Patients with poor knee alignment
  2. Patients who underwent meniscus surgery or rich plasma therapy
  3. Patients with or history of knee ligament injury
  4. Diabetic patients with poor glycemic control
  5. Patients with the following complications and poor general condition

    • Severe cardiovascular disease
    • Severe liver disease
    • Severe renal dysfunction
    • Severe anemia・uncontrolled mental illness
    • Other diseases for which sudden change or worsening of symptoms can be expected during study participation
  6. Patients who are pregnant or possibly pregnant and/or breast-feeding, or patients planning to become pregnant during the study period
  7. Other
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Biological: human autologous synovial stem cells

Interventions

  • Biologicalhuman autologous synovial stem cells

    A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy

06

What researchers measure

Primary outcomes

  1. Lysholm score

    It consists of items that measure: pain, instability, locking, swelling, limp, stair climbing, squatting, and need for support. Lowest and highest scores are 0 and 100 (better), respectively.

    Time frame: Screening up to 52 weeks

Secondary outcomes

  1. Arthroscopic assessment of the meniscus

    The structure and function of the repaired meniscus will be assessed in terms of the presence, stability, and smoothness of the meniscus by arthroscopic imaging and MRI.

    Time frame: Meniscus repair up to 52 weeks

  2. Knee injury and osteoarthritis outcome score (KOOS)

    The KOOS consists of five subscales; Pain, other symptoms, function in daily living (ADL), function in sport and recreation (Sport/Rec) and knee related quality of life (QOL). Lowest and highest scores are 0 and 100 (better), respectively.

    Time frame: Screening up to the Day before injection,4,12,24 and 52 weeks

  3. Numerical Rating Scale (NRS)

    NRS consists of an 11-point scale to evaluate current knee pain where no pain is indicated by '0', and the worst pain imaginable by '10'.

    Time frame: Screening up to the Day before injection,4,12,24 and 52 weeks

  4. Kellgren Lawrence

    The Kellgren and Lawrence system is a common method of classifying the severity of osteoarthritis (OA) using five grades.

    Time frame: Screening up to 24 and 52 weeks

07

Study locations

4 sites
  • Medical corporation keimeikai Juko Osu hospital
    Aichi, Japan
  • Wakamatsu Hospital of the University of OccupationalOC and Environmental Health
    Fukuoka, Japan
  • Mie Prefectural General Medical Center
    Mie, Japan
  • Tokyo Medical and Dental University Hospital
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Mar 21, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 31, 2025
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05777967
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 21, 2023
Start date
Jan 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 2, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion